Initiation of psychotropic medication in hospitalized patients with COVID‐19: Association with clinical and biological characteristics

Inpatients with coronavirus disease 2019 (COVID‐19) show a high rate of neuropsychiatric manifestations, possibly related to a higher risk of serious illness or death. Use of psychotropic medications (PMs) indicates the presence of neuropsychiatric symptoms in COVID‐19 patients. So far, potential clinical predictors of use of PMs have not been much investigated. In order to extend research in this area, we aimed to investigate the prevalence of PM prescription among a sample of inpatients with COVID‐19 and to find potential predictors of initiation of PMs in these individuals.

[1]  P. McKeigue,et al.  Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study , 2021, BMC Medicine.

[2]  S. Kaiser,et al.  Toxicity of psychotropic drugs in patients with COVID-19: A systematic review , 2021, General Hospital Psychiatry.

[3]  N. Hoertel,et al.  Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study , 2021, Molecular Psychiatry.

[4]  B. Harvey,et al.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment , 2021, Biomedicine & Pharmacotherapy.

[5]  Paul J. Harrison,et al.  Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA , 2020, The Lancet Psychiatry.

[6]  S. Inouye,et al.  Delirium in Older Patients With COVID-19 Presenting to the Emergency Department , 2020, JAMA network open.

[7]  A. Ruiz,et al.  Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia , 2020, Frontiers in Aging Neuroscience.

[8]  M. Pandey,et al.  Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions , 2020, Neurological Sciences.

[9]  A. Gorji,et al.  A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View , 2020, Molecular Neurobiology.

[10]  Urvish K. Patel,et al.  Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis , 2020, BMJ Evidence-Based Medicine.

[11]  B. Viswanath,et al.  Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses , 2020, Asian Journal of Psychiatry.

[12]  S. Kremer,et al.  Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients , 2020, Critical Care.

[13]  D. Rujescu,et al.  Immune cell puzzle COVID-19: how do SARS-CoV infections contribute to psychiatric diseases? , 2020, European Archives of Psychiatry and Clinical Neuroscience.

[14]  V. Medici,et al.  Prevalence and prognostic value of Delirium as the initial presentation of COVID-19 in the elderly with dementia: An Italian retrospective study , 2020, EClinicalMedicine.

[15]  R. Emsley,et al.  Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations , 2020, BMC Medicine.

[16]  A. Fagiolini,et al.  Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches , 2020, Therapeutic advances in psychopharmacology.

[17]  P. Matthews,et al.  Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study , 2020, The Lancet Psychiatry.

[18]  J. Gómez-Arnau,et al.  Covid-19 treatment-induced neuropsychiatric adverse effects , 2020, General Hospital Psychiatry.

[19]  Amit N. Patel,et al.  Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. , 2020, The New England journal of medicine.

[20]  N. Manjunatha,et al.  Neuropsychiatric aspects of COVID-19 pandemic: A selective review , 2020, Asian Journal of Psychiatry.

[21]  Mario Plebani,et al.  Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis , 2020, The American Journal of Emergency Medicine.

[22]  A. Yahya,et al.  The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks. , 2020, The primary care companion for CNS disorders.

[23]  Paolo Fusar-Poli,et al.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[24]  A. Harky,et al.  The role of biomarkers in diagnosis of COVID-19 – A systematic review , 2020, Life Sciences.

[25]  C. Specchia,et al.  Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy , 2020, European heart journal.

[26]  J. Kohn,et al.  Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms , 2020, Brain, Behavior, and Immunity.

[27]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[28]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[29]  Mario Plebani,et al.  Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.

[30]  B. Stricker,et al.  Reference values for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-based prospective cohort study , 2018, Scientific Reports.

[31]  A. Altamura,et al.  The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data , 2017, Drugs in R&D.

[32]  M. Bousser.  Neuropsychiatric manifestations in , 2007 .

[33]  J. T. Barr.  What is the risk? , 1991, Risk analysis : an official publication of the Society for Risk Analysis.